PI3K Pathway Inhibition in HR+/HER2- mBC: Mechanistic Insights
Komal Jhaveri, MD, FACP
Kevin Kalinsky MD, MS
From Pathway to Patient: Clinical Advances in PI3K-Directed Therapy for HR+/HER2- mBC
Case in Point: Applying PI3K Combinations in Early Recurrent HR+/HER2- mBC
Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC
Lauren A. Byers, MD
Translating Clinical Data Into Multidisciplinary Practice for ES-SCLC
Luis Paz-Ares, MD, PhD
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From WCLC 2025
Transformative Insights: Latest Evidence for B7-H3 ADCs From WCLC and ESMO 2025
Mastering the Sequence: CELMoDs Across Treatment Lines
Sagar Lonial, MD, FACP
Noopur Raje, MD
Beyond the Horizon in Multiple Myeloma: Harnessing Novel CELMoD Mechanisms for Increased Antimyeloma Activity
Joshua Richter, MD
Why CELMoDs Matter in Myeloma
Case Application: Frontline Insights—Tackling Newly Diagnosed Myeloma
Case Application: Unlocking Relapsed/Refractory Myeloma With CELMoDs
Molecular Magic: Decoding the Unique Mechanism of CELMoDs
Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma
John M. Kirkwood, MD
Sapna Patel, MD
Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma
Hussein Tawbi, MD, PhD
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
Paolo A. Ascierto, MD
Loading...
We're glad to see you're enjoying Prova Education… but how about a more personalized experience?
Press cancel to remain on Prova Education. Press the link below or the continue button to keep going.